OncoTracker Patents – Insights & Stats (Updated 2023)

OncoTracker has a total of 41 patents globally, out of which 12 have been granted. Of these 41 patents, more than 78% patents are active. The United States of America is where OncoTracker has filed the maximum number of patents, followed by Europe and Hong Kong (S.A.R.). Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of OncoTracker.

OncoTracker was founded in 2014. OncoTracker is a cancer therapy innovation incubator specializing on the diagnosis and treatment of multiple myeloma, other B-cell malignancies, and related illnesses.

Do read about some of the most popular patents of OncoTracker which have been covered by us in this article and also you can find OncoTracker patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over OncoTracker patent portfolio.

How many patents does OncoTracker have?

OncoTracker has a total of 41 patents globally. These patents belong to 9 unique patent families. Out of 41 patents, 32 patents are active.

How Many Patents did OncoTracker File Every Year?

OncoTracker Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantOncoTracker Applications FiledOncoTracker Patents Granted
202312
202213
202114
20201
201951
201882
20178
201614
20151
20141

How many OncoTracker patents are Alive/Dead?

Worldwide Patents

OncoTracker Patent Portfolio

How Many Patents did OncoTracker File in Different Countries?

OncoTracker Worldwide Patent Filing

Countries in which OncoTracker Filed Patents

CountryPatent
United States Of America10
Europe5
Hong Kong (S.A.R.)4
Singapore2
Japan2
Brazil1
Philippines1
Malaysia1
Canada1
Saudi Arabia1
Indonesia1
South Africa1
Israel1
Norway1
India1
Russia1
Italy1
Denmark1
Australia1
Korea (South)1
Spain1
Mexico1

Where are Research Centers of OncoTracker Patents Located?

R&D Centres of OncoTracker

Best OncoTracker Patents

US10126301B2 is the most popular patent in the OncoTracker portfolio. It has received 2 citations.

Below is the list of 10 most cited patents of OncoTracker:

Publication NumberCitation Count
US10126301B22
US20190107541A12
US20200326339A12
US20220000872A12
KR1020180033232A2
US10363260B21
US20180214553A11

What Percentage of OncoTracker US Patent Applications Were Granted?

OncoTracker (Excluding its subsidiaries) has filed 8 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 3 have been granted leading to a grant rate of 100%.

Below are the key stats of OncoTracker patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for OncoTracker?

Law FirmTotal ApplicationsSuccess Rate
Cooley Llp4100%
Stites & Harbison Pllc40%

List of OncoTracker patents

OncoTracker PatentsTitle
US11246876B2Anti-Cancer Effects Of Jak2 Inhibitors In Combination With Thalidomide Derivatives And Glucocorticoids
US10363260B2Anti-Cancer Effects Of Jak2 Inhibitors In Combination With Thalidomide Derivatives And Glucocorticoids
US10126301B2Diagnostic, Prognostic, And Monitoring Methods For Multiple Myeloma, Chronic Lymphocytic Leukemia, And B-Cell Non-Hodgkin Lymphoma
US11698369B2Methods For Monitoring Immune Status Of A Subject
US11635435B2Diagnostic, Prognostic, And Monitoring Methods For Solid Tumor Cancers
US20230233579A1Anti-Cancer Effects Of Jak2 Inhibitors In Combination With Thalidomide Derivatives And Glucocorticoids
US20190107541A1Diagnostic, Prognostic, And Monitoring Methods For Multiple Myeloma, Chronic Lymphocytic Leukemia, And B-Cell Non-Hodgkin Lymphoma
US20200326339A1Improved Methods For Monitoring Immune Status Of A Subject
US20220000872A1Method Of Enhancing Immune-Based Therapy
EP3402515B8Improved Methods For Monitoring Immune Status Of A Subject
EP3662909A1Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
EP3873478A4Method Of Enhancing Immune-Based Therapy
EP4079320A1Improved Methods For Monitoring Immune Status Of A Subject
CA2992557A1Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
JP7178902B2Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
JP2021167339AGamma Secretase Modulators For Treatment Of Immune System Dysfunction
IT202100092552T2Improved Methods For Monitoring A Subject’S Immune Status
DK3402515T3Improved Methods For Monitoring The Immune Status Of An Individual
ES2898329T3Improved Methods For Monitoring The Immune Status Of A Subject
RU2748655C2Gamma-Secretase Inhibitors For Treatment Of Immune System Dysfunction
NO3402515B1Improved Methods For Monitoring Immune Status Of A Subject
HK40031928AGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
SG10201913841SAGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
HK1255694AGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
PH12018500187A1Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
KR1020180033232AGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
ZA201800917AGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
HK40007456A1Improved Methods For Monitoring Immune Status Of A Subject
MX2018000999AGamma Secretase Modulators For The Treatment Of Immune System Dysfunction.
MYPI2018000083A0Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
SA518390791AGamma Secretase Levels To Treat Immune System Dysfunction
HK40082699AImproved Methods For Monitoring Immune Status Of A Subject
US20180214553A1Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
EP3324965A4Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
WO2020092792A3Method Of Enhancing Immune-Based Therapy
AU2016297793A1Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction
IL256903AGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
IN201817005810AGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
ID201807955AGamma Secretase Modulations For The Treatment Of Immunity System Disfusion
SG11201800566YAGamma Secretase Modulators For The Treatment Of Immune System Dysfunction
BR112018001480A2Gamma Secretase Modulators For The Treatment Of Immune System Dysfunction

What are OncoTracker key innovation segments?

What Technologies are Covered by OncoTracker?

The chart below distributes patents filed by OncoTracker in different countries on the basis of the technology protected in patents. It also represents the markets where OncoTracker thinks it’s important to protect particular technology inventions.

R&D Focus: How has OncoTracker search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by OncoTracker?

Related Articles

Leave a Comment

Fill the form to get the details:

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.